Current Edition

Europe

NICE nod for Novartis’ Luxturna

by Anna Smith The National Institute for Health and Care Excellence (NICE) has recommended the use of Luxturna (voretigene neparvovec) on the NHS, Novartis has ann...
Continue Reading →
news

FDA Urges Inclusion Of Men In Breast Cancer Clinical Trials

Men with breast cancer have significantly fewer treatment options than women with the disease, partly due to exclusion from many clinical trials. A new document f...
Continue Reading →
news

FDA grants Fast Track designation for Farxiga in chronic kidney disease

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to dela...
Continue Reading →
Europe

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure

AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint ...
Continue Reading →
news

Lilly’s case for Taltz helped by expanded approval

Credit: Eli Lilly & Co. Eli Lilly on Monday won an expanded approval for its psoriasis and arthritis drug Taltz, securing a Food and Drug Administration OK t...
Continue Reading →
Europe

AstraZeneca’s Breztri scores in COPD trial, amping its case for triple-combo battle against GSK

Could "orphan drug" status for Fasenra and a Breztri trial win give AstraZeneca a leg up in its battle against GlaxoSmithKline? (AstraZeneca) AstraZeneca and Gla...
Continue Reading →
news

Spurned by FDA a decade ago, Kyowa Kirin wins nod for Parkinson’s drug

Kyowa Kirin has won FDA nod for Nourianz as an add-on treatment to levodopa/carbidopa in adult Parkinson’s disease patients experiencing "off" episodes. (Pixabay/st...
Continue Reading →
news

AstraZeneca’s Farxiga pads its case for new heart-helping approval

AstraZeneca's Farxiga showed positive data in reducing cardiovascular risks in a new outcomes trial. (AstraZeneca) AstraZeneca is still stinging after its SGLT2 ...
Continue Reading →
Europe

AstraZeneca’s Imfinzi-tremelimumab duo flops another late-stage lung cancer trial

AstraZeneca is still testing Imfinzi on its own and in tandem with chemo in stage 4 lung cancer. (AstraZeneca) AstraZeneca has had high hopes for an immuno-oncol...
Continue Reading →
Europe

Medicines Co. awaits its date with destiny

Investors in The Medicines Company have Sept. 2 circled in red on their calendars. That's the day the company plans to report the first pivotal results from late-...
Continue Reading →